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Abstract
Cerebral palsy occurs in three to four infants per 1000 live births. Preterm birth prior to 34 weeks’
gestation is a major risk factor. Five randomized controlled trials of antenatal magnesium sulfate
(MgSO4) found a trend of reduced risk of cerebral palsy and mortality in preterm infants. Three meta-
analyses using the data from the five randomized controlled trials, which included a total of 5235
prospectively evaluated fetuses, found that MgSO4 given to women at risk of premature birth
significantly reduced the risk of cerebral palsy by 30% without increasing the risk of perinatal or infant
death. The implication for clinical practice is that MgSO4 should be considered for use in patients at
high risk of delivery before 34 weeks’ gestation.
Introduction and context
The cause of cerebral palsy (CP) is for the most part
unknown.CP occurs in three to four infants per 1000 live
births, resulting in 800,000 affected individuals in the
US. Preterm birth is a major risk factor: 25% of CP cases
occur in the 3.4% of infants born prior to 34 weeks’
gestation. The lifetime economic cost for the care of
patients with CP in the US born in 2000 was estimated to
be $11.5 billion (in 2003 dollars) [1].
The use of magnesium sulfate (MgSO4) for seizure
prevention in patients with pre-eclampsia and later as a
tocolytic agent in premature labor led to serendipitous
observations suggesting that infants exposed to MgSO4
in late pregnancy were less likely to develop CP
compared with infants born at similar gestational ages
who were not exposed to MgSO4 [2-4]. In 1995, Nelson
and Grether [5] published the first case-controlled study
of the possible neuroprotective effect of MgSO4 on 42
infants (birth weight <1500 g) with moderate or severe
CP surviving to age 3 years compared to 75 control
infants. The odds ratio for exposure to magnesium
during the delivery admission was 0.14 (0.05-0.51).
This effect persisted after control for other tocolytics,
steroids, and the indication for MgSO4 treatment [5].
Recent advances
Subsequent to the study by Nelson and Grether, six other
retrospective case-controlled studies were published
[6-11], only one of which demonstrated a statistically
significant reduction in neurological injury related to
maternal MgSO4 treatment [9]. In addition, one of two
retrospective cohort studies including a total of 2202
infants found a statistically significant reduction in the
odds ratio for untoward neurological outcome [12,13].
As a consequence of the favorable outcome in some of
the retrospective studies, five randomized controlled
trials were subsequently conducted to assess the hypoth-
esis that antenatal MgSO4 reduces the risk of CP and
mortality in preterm infants (Table 1) [14-18]. Inclusion
and exclusion criteria and dosage and timing of MgSO4
varied somewhat among the studies. Primary and
secondary neonatal outcomes included, among other
things, neonatal death and varying manifestations of
neurological injury, including CP. Using endpoints of
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result of neonatal death masking the risk of CP), some,
though not all, of the five trials found a trend of reduced
risk of death or CP, though in only one trial, albeit the
largest of the five, was the reduction in the risk of CP
statistically significant [18].
To avoid the problem of small sample size, there have
been three meta-analyses using the data from the five
randomized controlled trials [19-21]. These meta-
analyses, which include a total of 5235 prospectively
evaluated fetuses, benefit from being robust and
homogeneous. The results of these three meta-analyses
show convincingly that MgSO4 given to women at risk
of premature birth significantly reduces the risk of CP
by 30% without increasing the risk of perinatal or infant
death. The meta-analyses confirm the results of the
largest of the randomized controlled trials that assessed
the neuroprotective benefit of MgSO4 [18]. Conde-
Agudelo and Romero [20] calculated that to prevent 1
case of CP, 52 women at risk for preterm delivery at less
than 34 weeks’ of gestation would have to be treated
with MgSO4. In another analysis, Constantine and
Weiner [19] estimated that the number needed to
treat at less than 32-40 weeks’ gestation is 56 and at less
than 30 weeks’ gestation is 46.
Because of the varying dose and timing of MgSO4 in
the randomized controlled trials, the ideal treatment
regimen has not been established. Dosage in the trials
varied from a loading dose of 4 g in 15 minutes to 6 g
in 20 minutes, with maintenance infusion varying
from none to 3 g per hour, and duration of infusion
varying from 12 to 24 hours. These studies confirm
that the protective effect of MgSO4 occurs when
t r e a t m e n ti sa d m i n i s t e r e du pt o3 4w e e k s ’ gestation.
Only one of the randomized controlled trials included
patients randomized beyond 34 weeks’ gestation [16];
consequently, the benefit of using MgSO4 beyond 34
weeks’ gestation for its neuroprotective effect has not
been established. Nor has the neuroprotective effect of
MgSO4 been established for multiple gestations, but
this may be due to the relatively few number of twin
gestations that were included. In the largest trial,
though not statistically significant, the risk reduction
for twins was of the same magnitude as for singletons
[18]. Other important clinical issues that were not
addressed consistently in the randomized controlled
trials include the use of MgSO4 in conjunction with
tocolytic medications for preterm labor and retreat-
ment regimens if delivery does not occur. Addressing
the issue of retreatment, the protocol in the Beneficial
Effects of Antenatal Magnesium Sulfate (BEAM) trial
Table 1. Randomized controlled trials: effect of magnesium sulfate treatment for expected premature birth on risk of perinatal death or
cerebral palsy (CP)
Study Country;
no. of location
centers;
no. of countries;
no. of subjects
Inclusion No. of infants Regimen:
initial dose;
maintenance
CP RR (95% CI);
combined perinatal
death & CP
RR (95% CI)
MagNET
Mittendorf et al. [14]
US
1
1
149
25-33 weeks
PTL
165 4 g
2-3 g/hr*
Not significant (of n = 3
in both treated and
placebo group)
n/a
ACTOMgSO4
Crowther et al. [15]
Australia
16
2
1062
<30 weeks 1255 4 g/20 mins
1 g/hr (not to exceed
24 hrs)
0.85 (0.56-1.31)
0.83 (0.66-1.03)
Magpie Trial
Duley et al. [16]
International
125
19
1544
<37 weeks
Severe pre-eclampsia
1593 4 g/10-15 mins
1 g/hr (for 24 hrs)
0.66 (0.11-3.94)
1.06 (0.09-1.25)
PREMAG
Marret et al. [17]
France
13
1
573
<33 weeks
PTL
688 4 g/30 mins
No maintenance
0.70 (0.41-1.19)
0.86 (0.55-1.34)
BEAM
Rouse et al. [18]
US
20
1
2241
24-31 weeks
High risk of
spontaneous birth
2444 6 g/20-30 mins
2 g/hr (for 12 hrs)
0.59 (0.40-0.85)
0.97 (0.77-1.23)
*36% of subjects were more than 4 cm dilated and received only the loading dose.
In each trial, evaluators of perinatal outcomes were blinded to treatment and all outcomes were based on intention to treat. ACTOMgSO4, Australasian
Collaborative Trial of Magnesium Sulfate; BEAM, Beneficial Effects of Antenatal Magnesium Sulfate; CI, confidence interval; MagNET, Magnesium and
Neurologic Endpoints Trial; PTL, preterm labor; RR, relative risk.
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Delivery expected
<24 hrsadvised repeating the loading dose if at least 6 hours
had passed since the discontinuation of the study
medication [18]. It is important to emphasize that at
low levels antenatal MgSO4 has beneficial neuropro-
tective effects and does not increase perinatal mortality
or morbidity in very preterm infants [22].
The most common lesion associated with CP in infants
born prematurely is periventricular white matter injury.
The precise mechanism of action for the neuroprotective
effect of MgSO4 in preterm infants is not known. Marret
et al. [23] and Conde-Agudelo and Romero [20] have
summarized the experimental evidence that supports
several possible neuroprotective effects of magnesium.
The ample biological rationale includes reduction of
inflammatory cytokines or free radicals produced during
hypoxic-ischemic reperfusion, prevention of excitotoxic
calcium-induced injury, membrane stabilization that
prevents the persistent membrane depolarization result-
ing from failure of the Na
+-K
+ ATP-dependent pump,
inhibition of ionotropic glutamate receptors that are
involved in injury to pre-oligodendrocytes, stabilization
of rapid fluctuations in blood pressure that occur in
neonates, and an increase in cerebral blood flow.
No maternal deaths and no life-threatening maternal
side effects occurred in the five randomized controlled
trials as a result of MgSO4 treatment [20]. Patients
exposed to MgSO4 had a 50% increase of both
hypotension and tachycardia compared with control
patients. Also, an increased proportion of women
receiving MgSO4 had a variety of side effects, including
flushing, nausea or vomiting, and sweating, compared
with control patients.
Implications for clinical practice
MgSO4 should be considered for use in patients at high
risk of delivery before 34 weeks’ gestation, including
during planned delivery, premature rupture of mem-
branes, or active labor. Until further studies have
determined a minimum effective dose and an optimum
time to administer it, a reasonable regimen is a loading
dose not exceeding 4 g, followed by a maintenance
infusion of 1-2 g per hour for 24 hours.
Pending further information (secondary analysis of the
prevention studies, animal data establishing an effective
minimum dose, and so on), we believe a reasonable
regimen to administer MgSO4 for neuroprotection
includes a 4 g bolus, 1 g per hour maintenance infusion,
and re-bolus if the MgSO4 has not been administered for
more than 6 hours. Given that it takes around 4 hours for
MgSO4 levels to reach a steady state in the fetus, we
attempt to begin the infusion at least 4 hours prior to
birth if possible, but would give it as late as 1 hour prior
to birth. The MgSO4 can be discontinued after 12 hours if
preterm birth no longer appears imminent. MgSO4
should not be given concurrently with calcium channel
blockers. We recommend that, if possible, MgSO4
infusion be postponed for 3-4 hours after the last dose
of a calcium channel blocker such as nifedipine.
However, if continued tocolysis is deemed necessary,
depending on the clinical circumstances, indomethacin
might be preferable to a calcium channel blocker.
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